Biofrontera Reports 30% Q3 Revenue Growth and 74.4% Gross Margin

Biofrontera reported third-quarter 2026 net product revenue of $9.1 million, up 29.8% year over year, and gross margin of 74.4%. Net loss was $6.4 million, or $0.42 per share, while adjusted EBITDA was a loss of $5.5 million. The quarter included FDA approval of Ameluz for superficial basal cell ca…